ALGINOR PHARMA INGREDIENTS AS

Operating

Bedriftsrådgivning, forretningsutvikling, investering, forskning og utvikling, innovasjon, produksjon, handel og distribusjon.

Industriell produksjon, farmasi.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

CEO: SM
Steen Mylius Stricker Lund1959
Chairman of the board: WK
Wenche Kjølås1962
Years since formation: 4 years; since Jan 11, 2022
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 100,000; 1 share class
Total number of shareholders: 1; company
Belongs to group of

Financials

Annual total result 2025: -27,037,022; NOK
Total equity 2025: 44,199; NOK

Last update: Aug 22, 2026

Management

Management / administration

Name	Role	Shares
SM Steen Mylius Stricker Lund 1959	Managing Director/CEO	-

Board

Name	Role	Shares
WK Wenche Kjølås 1962	Chairman	-
PA Per Arthur Sørlie 1957	Board Member	-
KK Kristine Klaveness 1976	Board Member	-
ML Martin Lersch 1976	Board Member	-
SS Sten Stenersen 1988	Board Member	-

Others

Name	Role	Shares
C CEDRA NORGE AS	Auditor	-

Top 10 individual shareholders

Name	Role	Shares
TM Trine Must 1971	-	8.55 % indirectly
EC Erik Christian Must 1973	-	8.54 % indirectly
ØH Øystein Hatteland 1992	-	2.08 % indirectly
HH Helge Hatteland 1995	-	1.43 % indirectly
SH Stig Hatteland 1980	-	1.43 % indirectly
HR Hatteland Ronny 1988	-	1.43 % indirectly
TH Tommy Hatteland 1990	-	1.43 % indirectly
RH Randi Hatteland 1978	-	1.43 % indirectly
JH Jakob Hatteland 1951	-	1.4 % indirectly

Last update: Aug 3, 2026

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
A ALGINOR ASA	Ordinary shares	100,000	100 %

Last update: Jun 2, 2025

Group structure

ALGINOR ASA
Total operating income 2025: NOK 2,980
Operating profit 2025: NOK -228,284,008
Employees: 17

Financials

in NOK

Summary

Year	2025	2024	2023	2022	2021
Total operating income	0	0	0	400,000	0
Annual Total Result	-27,037,022	-228,255	92,181	-89,493	0
Total assets	22,503,673	33,037,515	18,764,620	10,394,757	100,000
Total liabilities	22,459,474	23,265,769	8,764,619	484,250	0
Total equity	44,199	9,771,746	10,000,001	9,910,507	100,000

P&L

Year	2025	2024	2023	2022
Total operating income	0	0	0	400,000
Total operating costs	27,043,768	317,096	55,068	489,493
Operating result	-27,043,768	-317,096	-55,068	-89,493
Financial income/costs	6,746	88,841	148,007	0
Profit before tax	-27,037,022	-228,255	92,939	-89,493
Total tax & extraordinary income/cost	0	0	758	0
Annual Total Result	-27,037,022	-228,255	92,181	-89,493

Balance overview

Year	2025	2024	2023	2022	2021
Total fixed assets	0	26,757,372	10,433,186	2,434,034	0
Total current assets	22,503,673	6,280,144	8,331,433	7,960,723	100,000
Total assets	22,503,673	33,037,515	18,764,620	10,394,757	100,000
Short term debt	22,459,474	23,265,769	8,764,619	484,250	0
Long term debt	0	0	0	0	0
Total liabilities	22,459,474	23,265,769	8,764,619	484,250	0
Contributed capital	10,000,000	10,000,000	10,000,000	10,000,000	100,000
Retained earnings	-9,955,801	-228,254	1	-89,493	0
Total equity	44,199	9,771,746	10,000,001	9,910,507	100,000
Total equity and liabilities	22,503,673	33,037,515	18,764,620	10,394,757	100,000

Classification

21st company classification

BETA

Small company

ALGINOR PHARMA INGREDIENTS AS928 521 672